Compare Bristol-Myers Squibb Co (BMY) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Bristol-Myers Squibb Co trades at $58.37 (market cap $116.30B), while First Trust NASDAQ 100 Technology Index Fund trades at $315.21. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while First Trust NASDAQ 100 Technology Index Fund pays none. Which is the better fit depends on your goals.
| BMY | QTEC | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $62.37 | $335.74 |
52-Week Low | $42.60 | $207.03 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
QTEC trades at $312.20, down 2.75% today amid neutral technical signals and bearish moving average pressure. The ETF provides equal-weighted exposure to Nasdaq-100 technology stocks, with recent news highlighting its role in the AI and semiconductor sector. Support levels at $310 and $307 provide near-term downside protection while resistance sits at $316 and $319.
The technology sector ETF faces headwinds from valuation concerns in AI-related stocks but maintains strategic positioning for long-term tech growth. Key risks include sector concentration and market volatility, while institutional interest remains steady given the fund's targeted exposure to leading technology companies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
